Cargando…

Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial

BACKGROUND: Patients with both diabetes mellitus (DM) and chronic kidney disease (CKD) are a subpopulation characterized by ultrahigh ischemic and bleeding risk after percutaneous coronary intervention. There are limited data on the impact of ticagrelor monotherapy among these patients. METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Chao, Tomaniak, Mariusz, Takahashi, Kuniaki, Kawashima, Hideyuki, Wang, Rutao, Hara, Hironori, Ono, Masafumi, Montalescot, Gilles, Garg, Scot, Haude, Michael, Slagboom, Ton, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, van Geuns, Robert-Jan, Hamm, Christian, Steg, Philippe Gabriel, Onuma, Yoshinobu, Angiolillo, Dominick J., Serruys, Patrick W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568378/ https://www.ncbi.nlm.nih.gov/pubmed/33066794 http://dx.doi.org/10.1186/s12933-020-01153-x

Ejemplares similares

‘Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI’: a post hoc analysis of the randomized GLOBAL LEADERS trial
por: Gamal, Amr S, et al.
Publicado: (2021)

Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial
por: Vranckx, Pascal, et al.
Publicado: (2021)

Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial
por: Gragnano, Felice, et al.
Publicado: (2022)

The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial
por: Ono, Masafumi, et al.
Publicado: (2020)

Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond
por: Wang, Rutao, et al.
Publicado: (2021)

Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial
por: Ono, Masafumi, et al.
Publicado: (2022)

Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events
por: Kawashima, Hideyuki, et al.
Publicado: (2020)

Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)
por: Leonardi, Sergio, et al.
Publicado: (2019)

Commentary: Ticagrelor monotherapy—Not for CABG?
por: Sandner, Sigrid, et al.
Publicado: (2022)

Age‐Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial
por: Kim, Byung Gyu, et al.
Publicado: (2021)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
por: Valgimigli, Marco, et al.
Publicado: (2021)

When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y(12) Inhibition Induced by Ticagrelor
por: Capodanno, Davide, et al.
Publicado: (2020)

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention
por: Sweeny, Joseph M., et al.
Publicado: (2017)

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
por: Magnani, Giulia, et al.
Publicado: (2021)

Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease
por: Wang, Rutao, et al.
Publicado: (2021)

Ticagrelor monotherapy after CABG—Probably not at all and definitely not forever
por: Sandner, Sigrid, et al.
Publicado: (2022)

Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management
por: Ortega‐Paz, Luis, et al.
Publicado: (2021)

P2Y(12) Inhibitor Monotherapy after Percutaneous Coronary Intervention
por: Zhou, Xuan, et al.
Publicado: (2022)

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
por: Dellborg, Mikael, et al.
Publicado: (2019)

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
por: Angiolillo, Dominick J., et al.
Publicado: (2021)

Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging
por: Ono, Masafumi, et al.
Publicado: (2020)

Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study
por: Wang, Rutao, et al.
Publicado: (2021)

A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease
por: Price, Matthew J., et al.
Publicado: (2014)

Long-term monotherapy with ticagrelor after coronary stenting: the GLOBAL LEADERS study
por: Greco, Antonio, et al.
Publicado: (2020)

Letter to the editor in response to Kobo et al. 2022
por: Kageyama, Shigetaka, et al.
Publicado: (2022)

Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
por: Åstrand, Magnus, et al.
Publicado: (2018)

Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease
por: Wang, Rutao, et al.
Publicado: (2021)

Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study
por: Wang, Rutao, et al.
Publicado: (2021)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)

Adherence of ticagrelOr in real world patients with aCute coronary syndrome: The AD-HOC study
por: Fiocca, Luigi, et al.
Publicado: (2022)

De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis
por: Angiolillo, Dominick J., et al.
Publicado: (2019)

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment
por: Bergmeijer, Thomas O., et al.
Publicado: (2018)

Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial
por: Baos, Sarah, et al.
Publicado: (2017)

Body mass index affecting ticagrelor monotherapy vs. ticagrelor with aspirin in patients with acute coronary syndrome: A pre-specified sub-analysis of the TICO randomized trial
por: Kim, Byung Gyu, et al.
Publicado: (2023)

Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis
por: García-García, Héctor M., et al.
Publicado: (2011)

Quantitative Angiographic Assessment of Aortic Regurgitation After Transcatheter Implantation of the Venus A-valve: Comparison with Other Self-Expanding Valves and Impact of a Learning Curve in a Single Chinese Center
por: Wang, Rutao, et al.
Publicado: (2021)

Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial
por: Yun, Kyeong Ho, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8465b2nit4vb9bhv6a88qjugct